XYLOCAINE 1.5% W EPINEPHRINE 1:200000 15 MG
LIDOCAINE HYDROCHLORIDE : 15 MG EPINEPHRINE : 5 MCG · DIN 00001813 · ASTRAZENECA CANADA INC
Health Canada status: CANCELLED POST MARKET
What is XYLOCAINE 1.5% W EPINEPHRINE 1:200000?
XYLOCAINE 1.5% W EPINEPHRINE 1:200000 15 MG contains LIDOCAINE HYDROCHLORIDE : 15 MG EPINEPHRINE : 5 MCG. It is listed in the Health Canada Drug Product Database under DIN 00001813, held by ASTRAZENECA CANADA INC, supplied as LIQUID for BLOCK/INFILTRATION administration. Health Canada currently lists it as cancelled post market, status dated 21-Dec-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XYLOCAINE 1.5% W EPINEPHRINE 1:200000 used for?
Production of local or regional anesthesia by infiltration, peripheral nerve block (e.g., brachial plexus), and central neural techniques (e.g., epidural and caudal blocks).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00001813 |
|---|---|
| Brand name | XYLOCAINE 1.5% W EPINEPHRINE 1:200000 |
| Generic / active ingredient | LIDOCAINE HYDROCHLORIDE : 15 MG EPINEPHRINE : 5 MCG |
| Manufacturer | ASTRAZENECA CANADA INC |
| Strength | 15 MG |
| Dosage form | LIQUID |
| Route of administration | BLOCK/INFILTRATION |
| Schedule | Ethical |
| ATC code | N01BB52 LIDOCAINE, COMBINATIONS |
| AHFS class | 72:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 21-Dec-2011 |
| Original market date | 1955-12-31 00:00:00 |
How is it administered?
Use lowest effective dose. Injections should be slow with frequent aspiration. Pediatric dose: up to 5 mg/kg (7 mg/kg with epinephrine). Reduce dose for elderly/debilitated patients.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (Table of Contents refers to page 24, but text ends earlier).
How is it supplied?
Multidose vials and other presentations (refer to product label).
Contraindications
Hypersensitivity to amide local anesthetics, sodium metabisulfite, citric acid, or parabens. Preservative-containing solutions are contraindicated for epidural, spinal, or intra-ocular use.
Warnings and precautions
Should only be used by clinicians versed in toxicity management. Risk of irreversible chondrolysis with unapproved intra-articular infusion. Risk of systemic toxicity and cardiac arrest.
What can be used instead?
Other Canadian products sharing ATC code N01BB52 LIDOCAINE, COMBINATIONS. 16 of 72 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| INSTILLAGEL | 0.05 % | GEL | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02294990 |
| LIDOCAINE 2% AND EPINEPHRINE 1:100,000 | 20 MG | SOLUTION | SEPTODONT | MARKETED | DIN 02473518 |
| LIDOCAINE 2% AND EPINEPHRINE 1:50,000 | 20 MG | SOLUTION | SEPTODONT | MARKETED | DIN 02473526 |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | 0.01 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02436221 |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | 20 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 01901915 |
| LIGNOSPAN FORTE | 36 MCG / 1.8 ML | SOLUTION | SEPTODONT | MARKETED | DIN 00375799 |
| LIGNOSPAN STANDARD | 36 MG / 1.8 ML | SOLUTION | SEPTODONT | MARKETED | DIN 00375780 |
| OCTOCAINE HCL 2% EPINEPHRINE 1:100000 | 0.01 MG | SOLUTION | NOVOCOL PHARMACEUTICAL OF CANADA INC | MARKETED | DIN 00151866 |
| PLIAGLIS | 7 % | CREAM | SCIENCES DE LA PEAU CRESCITA INC. / CRESCITA SKIN SCIENCES INC. | MARKETED | DIN 02398028 |
| XYLOCAINE 1% W EPINEPHRINE 1:100000 | 10 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 00001791 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.